On September 1, 2017, the U.S. Food and Drug Administration approved gemtuzumab ozogamicin (Mylotarg, Pfizer Inc.) for the treatment of newly-diagnosed CD33-positive acute myeloid leukemia (AML) in adults and for treatment of relapsed or refractory CD33-positive AML in adults and in pediatric patients 2 years and older.
ASCO in Action regularly provides the latest news and analysis related to cancer policy news; see the following online articles. These updates provide snapshots of ASCO’s ongoing advocacy efforts, as well as opportunities for ASCO members and guests to take action on critical issues affecting the cancer community.
To sign up for advocacy alerts, log in to ASCO.org with your ASCO member or guest account, and visit the subscription center available under your account profile.
ASCO has announced that the first three practices in Spain have received Quality Oncology Practice Initiative (QOPI®) certification through QOPI Certification Program™, LLC (QCP). The accreditations were given today at the European Society of Medical Oncology (ESMO) 2017 Congress in Madrid, Spain.
A new study published in the Journal of Clinical Oncology has found that under the Affordable Care Act (ACA), the percentage of uninsured nonelderly cancer patients declined substantially and early diagnosis increased, especially among low-income populations residing in Medicaid expansion states.
Early this fall, physicians will be able to access their 2016 Annual Quality and Resource Use Reports (QRURs). These reports show how groups and solo practitioners performed in 2016 on the quality and cost measures used to calculate the 2018 Value-Based Payment Modifier. ASCO members can prepare to access their QRURs now by signing up for an Enterprise Identity Management (EIDM) account or by ensuring their current account is active. An EIDM account is required to obtain QRURs.
CancerLinQ LLC, a wholly owned nonprofit subsidiary of ASCO, has announced that West Cancer Center in Tennessee has signed an agreement to participate in the CancerLinQ® platform.
In August, CancerLinQ® was featured in two articles that focused on CancerLinQ LLC’s recently announced partnerships with the Food and Drug Administration and National Cancer Institute.
ASCO is committed to supporting cancer care providers and patients affected by the recent hurricanes. The society has assembled a list of resources to aid cancer patients, caregivers, and providers, including patient-focused assistance from Cancer.Net, regional state oncology societies contact information, and links to resources from the National Cancer Institute.
On August 30, 2017, the U.S. Food and Drug Administration granted regular approval to tisagenlecleucel (KYMRIAH®, Novartis Pharmaceuticals Corp.) for the treatment of patients up to age 25 years with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
ASCO recently submitted comments to the House Ways and Means Health Subcommittee regarding its “Medicare Red Tape Relief Project, which aims to alleviate the regulations and mandates in the Medicare program that impede innovation, increase costs, and prevent the delivery of better care to beneficiaries.
On August 25, a new article published in JCO Clinical Cancer Informatics, “Automating QOPI Quality Measure NHL78a,” reports how the authors were able to use data from an electronic health record and Microsoft SQL Server database management system to complete the Quality Oncology Practice Initiative (QOPI®) measure NHL 78a, which addresses Hepatitis B testing in patients with non-Hodgkin lymphoma.
Healthcare-related financial distress remains a prevalent issue in the United States. Financial distress is common among patients with cancer who may face significant out-of-pocket costs. Further, this distress is not only an economic concern for the patient and their family, but has also been associated with lower quality of life.
A new, national study finds there is a critical need to better integrate geriatric education into oncology fellowship training. The study, sponsored by the American Society of Clinical Oncology, and published in Journal of Oncology Practice (JOP), evaluated hematology/oncology fellows’ education, clinical experiences, and perceived proficiency in geriatric oncology.
Based on data from two recently halted clinical trials, the U.S. Food and Drug Administration today is issuing this statement to inform the public, health care professionals, and oncology clinical investigators about the risks associated with the use of KEYTRUDA® (pembrolizumab) in combination with dexamethasone and an immunomodulatory agent (lenalidomide or pomalidomide) for the treatment of patients with multiple myeloma. KEYTRUDA® (pembrolizumab) is not approved for treatment of multiple myeloma.
Oncology practices across the country are currently implementing the Quality Payment Program. In 2017, practices have minimal reporting requirements in order to avoid financial penalties in 2019, but ASCO encourages practices to report on at least four measures to become fully acquainted with the system and to ensure that CMS requirements are met. Practices that can report a bit more data may also try to earn a small positive payment adjustment in 2019. Is your practice thinking about trying to earn a small positive payment adjustment? Here are the top five things you need to know.